Clinical Trials

Dr. David Tran is the principle investigator, faculty sponsor, and/or study chair of the following investigator-initiated clinical trials:

PRECISION: A Phase II Study of the NovoTTF-100A System, Enhanced by Genomic Analysis to Identify the Genetic Signature of Response in the Treatment of Recurrent Glioblastoma.

PROGRESS: A Phase I and Open Label, Randomized, Controlled Phase II Study Testing the Safety, Toxicities, and Efficacy of MK-3475 (PD-1 inhibitor) in combination with MRI-guided Laser Ablation in Recurrent Malignant Gliomas.

PULSED AVASTIN: Phase 2, Single arm, historically controlled study testing the combination of TTFields and Pulsed Bevacizumab treatment in patients with bevacizumab-refractory recurrent GBM.

A Dose Finding Phase 1 of Sarilumab plus Capecitabine in HER2/neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab plus Capecitabine in Stage I-III Triple Negative Breast Cancer with High-Risk Residual

2-THE-TOP: Phase 2, single arm, historically controlled study testing the combination of adjuvant Temozolomide plus TTFields plus Pembrolizumab in patients with newly diagnosed glioblastoma.

Visit the UF Health Neurosurgery Clinical Trials page for a full list of current neurosurgery clinical trials.